|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Sankyo Pharma Gmbh |
| Information provided by: | Daiichi Sankyo Inc. |
| ClinicalTrials.gov Identifier: | NCT00151827 |
Purpose
This is a study in hypertensive patients with mild to moderate renal impairment. The antihypertensive efficacy of olmesartan medoxomil is compared to losartan.
| Condition | Intervention | Phase |
|
Essential Hypertension Renal Impairment |
Drug: Olmesartan medoxomil Drug: Losartan Drug: Furosemide |
Phase III |
| Genetics Home Reference related topics: | Kidney Diseases |
| MedlinePlus related topics: | High Blood Pressure Kidney Diseases |
| ChemIDplus related topics: | Losartan potassium Losartan Furosemide Olmesartan Olmesartan medoxomil |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment |
| Estimated Enrollment: | 400 |
| Study Start Date: | August 2003 |
| Estimated Study Completion Date: | February 2006 |
Eligibility
| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | SE-866/43 |
| First Received: | September 8, 2005 |
| Last Updated: | October 11, 2007 |
| ClinicalTrials.gov Identifier: | NCT00151827 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|